Compare ASG & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASG | LYEL |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.1M | 320.1M |
| IPO Year | 1995 | 2021 |
| Metric | ASG | LYEL |
|---|---|---|
| Price | $5.06 | $9.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $37.88 |
| AVG Volume (30 Days) | ★ 237.9K | 105.0K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.55 | $9.45 |
| 52 Week High | $5.69 | $45.00 |
| Indicator | ASG | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 27.89 |
| Support Level | $4.98 | N/A |
| Resistance Level | $5.27 | $15.38 |
| Average True Range (ATR) | 0.05 | 0.52 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 67.57 | 12.67 |
Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company's portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.